SOURCE: ChromoCure, Inc.

February 08, 2010 08:30 ET

ChromoCure's Technology and Theoretical Approach to Cancer Further Affirmed by Recent $720,000 Donation to The Cancer Society for Aneuploidy Research

RENO, NV--(Marketwire - February 8, 2010) -  ChromoCure, Inc. (PINKSHEETS: KKUR) -- The Company announces that, on the heals of launching its groundbreaking collaborate cancer therapeutics and cure initiative: "Project Boveri: Find the Cure," it is encouraged by the recent donation by Dr. Lawrence Tseu, a retired Honolulu dentist and noted philanthropist, and whose late wife was a long time cancer patient, of $720,000 to the American Cancer Society Hawaii Pacific for research to stop breast cancer from spreading to other parts of the body utilizing the chromosomal (aneuploidy) theory of Cancer.

Wael ElShamy, a Cancer Research Center of Hawaii researcher, discovered that a certain molecule plays a key role in breast cancer metastasis, ACS said. When the molecule is active in breast cancer cells, it promotes an abnormal number of chromosomes, called aneuploidy. Jackie Young, ACS Hawaii Pacific chief staff officer for mission, said, "This very generous gift will fund an important research project that could improve how breast cancer is treated and dramatically increase the survival rate."

ChromoCure has long championed the chromosomal/aneuploidy theory of cancer. This theory has been proven by recent findings by third party research and publications including the Mayo Clinic. The company therefore announced the launch of its Cancer Therapy and Cure initiative, "Project Boveri: Find the Cure"; a collaborative expansion of its research into detecting cancer in its earliest stages, greatly aiding the ability to treat or cure it.

Not only has ChromoCure's theoretical approach to cancer been validated, its proprietary Chromosomal Scanner technology, as demonstrated in the Company's recently published collaborative clinic testing, has been proven a reliable and effective automated technological system to detect aneuploid cells in real-world specimens, that detection of aneuploid cells is diagnostic of cervical lesions, and that the Chromosomal Scanner possesses superb performance at not only detecting cancer but achieving the near theoretical maximum agreement with the clinic's error containing data.

The Company's proprietary technology and pioneering knowledge of cancer's chromosomal properties invites very effective, non-toxic therapeutic and disease eradication strategies. ChromoCure's understanding of cancer's chromosomal peculiarities provides the most promising avenue for treatment and cure and reinforces its pioneering status.

About ChromoCure

ChromoCure develops proprietary technologies based on the chromosomal theory of cancer. The Company has proprietary technology, designs, protocols, and algorithms for cancer detection. The Company's technology has been proven to have an effective accuracy of 100% for all cancers at all stages with zero false positives or false negatives and an effective 100% specificity. The Company believes its technology will become the worldwide gold standard for cancer detection, therapy and cure research. The Company also applies its technology and understanding of cancer's unique genomic characteristics in the area of therapeutics and disease eradication as part of its ongoing research efforts.

Safe-Harbor Statement
This release contains statements or projections regarding future performance that is forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company's filings contain various RISK FACTORS (and are incorporated herein by reference) and should be read before any investment decision.

Contact Information